Alaxo Airway Stents (Alaxo) and Singular Sleep (Singular) Announce They Have Formed a Partnership
Dr. Joseph Krainin and Mr. Terry Bayliss Report
PHOENIX, November 12, 2020 (Newswire.com) - Alaxo and Singular announce they have formed a partnership to deliver solutions to help people deal with sleep apnea.
"We are pleased to partner with Singular,” said Terry Bayliss, CEO of Alaxo. “As people continue to adapt to the struggles created by the CoVID-19 pandemic, those healthcare providers who use telemedicine realize this is the way of future health delivery. Our partnership with Singular lends to our combined ability to provide a complete sleep solution for our customers throughout the United States.”
Dr Krainin states, “We are enthusiastic about this collaboration with Alaxo to offer a new ‘alternative to CPAP’ treatment. I am constantly looking for new, FDA-approved treatments for my patients who have failed CPAP and the Alaxo Airway Stents are an exciting new treatment modality.”
About Singular Sleep
Singular Sleep is the first-ever completely online sleep center. Founded in 2015 by board-certified sleep doctor Dr. Joseph Krainin, the company specializes in the remote diagnosis and treatment of sleep apnea.
Alaxo offers FDA and Health Canada registered, internationally patented, innovative stent-based therapies to support healthy, natural, nasal breathing solutions for snoring, sleep apnea and enhanced athletic performance.
Made of nitinol, a nickel-titanium alloy that has super-elastic characteristics, our innovative stents support the upper airway passage to allow for better airflow and easier breathing.
The Alaxo product line is clinically proven to improve nasal breathing, improve sleep and enhance athletic performance. The AlaxoStent is clinically tested for treatment of patients struggling with obstructive sleep apnea or snoring.
We Seek Safe Harbor
Categories: Healthcare and Medical News